Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
492 results about "Altersbedingte makuladegeneration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Transscleral delivery
Diseases associated with the tissues in the posterior segment of the eye can be effectively treated by administering therapeutic agents transsclerally to those tissues. Compositions, devices, and methods for delivering therapeutic agents so that they cross the sclera and reach these tissues include injecting solutions or suspensions adjacent to or within the sclera and implanting solid structures containing the therapeutic agent adjacent to or within the sclera. These methods may be used for administering rapamycin or related compounds to treat choroidal neovascularization associated with age-related macular degeneration.
Owner:SANTEN PHARMA CO LTD
Treatment of age-related macular degeneration
Owner:XOFT INC +1
(5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
The present invention relates to compounds having the formula I: which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS7517870B2High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
Owner:FOND AZIONE TELETHON
Drug delivery systems and use thereof
InactiveUS20050175708A1Reduced inhibitory activityTreat and inhibit diseasePowder deliveryBiocideVascular endothelial growth factorDelivery system
The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration.
Owner:MASSACHUSETTS EYE & EAR INFARY
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00001.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00002.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00003.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
Owner:MERCK SHARP & DOHME CORP
Treatment of age-related macular degeneration using inhibitors of complement factor d
InactiveUS20080269318A1Avoid developmentInhibit the loss of visual acuityBiocideSenses disorderComplement Factor H GeneFactor ii
The present invention provides methods for identifying a patient at risk for developing AMD by identifying the presence of the Y402H polymorphism or other at risk variants in the complement factor H gene. The present invention further provides methods for treating persons having AMD or at risk for developing AMD as a result of having the Y402H polymorphism or other at risk variants in the complement factor H gene.
Owner:ALCON RES LTD
Intraocular devices and associated methods
Visual aids and associated methods for improving the eye sight of low vision patients are provided. Generally, the devices of the present disclosure address the needs of age-related macular degeneration (AMD) and other low vision patients by providing a magnified retinal image while keeping a large visual field of view. Further, the devices of the present disclosure allow direction of the magnified retinal image away from damaged portions of the retina and towards healthy, or at least healthier, portions of the retina. The devices of the present disclosure are also configured for implantation within the eye using minimally invasive surgical procedures. Methods of utilizing the devices of the present disclosure, including surgical procedures, are also provided.
Owner:ALCON INC
Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
This invention proposes that the best therapeutic strategy for treating and / or preventing Alzheimer's disease (AD), age related macular degeneration (AMD) and other diseases that exhibit extra-cellular debris deposits, such as atherosclerosis, is the inhibition of the complement pathway. A model for the accumulation of extra-cellular debris through the activation of the complement pathway is presented, and the primary pathogenic role of the debris in the etiology of the disorders is explained. Previously identified complement inhibitors are identified as therapeutic agents for the treatment and / or prevention of AD, AMD and other diseases that exhibit extra-cellular debris deposits.
Owner:DINU VALENTIN
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
InactiveUS20060067935A1Reduces VEGF expressionReduce expressionGenetic material ingredientsAntibody ingredientsIn vivoBiology
Activated C3 (C3a) and its receptor (C3aR) and activated C5 (C5a) and its receptor (C5aR) have been shown to induce vascular endothelial growth factor (VEGF) expression in vitro and in vivo. Compositions and methods for inhibiting C3a, C3aR, C5a and C5aR for the treatment and / or prevention of neovascular disease are provided. Also provided are Novel therapeutic targets and diagnostic markers for choroidal neovascularization.
Owner:KENTUCKY UNIVERISTY OF
Text capture and presentation device
Embodiments of the invention provide devices and methods for capturing text found in a variety of sources and transforming it into a different user-accessible formats or medium. For example, the device can capture text from a magazine and provide it to the user as spoken words through headphones or speakers. Such devices are useful for individuals such as those having reading difficulties (such as dyslexia), blindness, and other visual impairments arising from diabetic retinopathy, cataracts, age-related macular degeneration (AMD), and glaucoma.
Owner:CARE INNOVATIONS LLC
Use of complement inhibitors to treat ocular diseases
Owner:GENENTECH INC
Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
InactiveUS20080280987A1Inhibit angiogenesisSignificant cytotoxicityBiocideSenses disorderDiabetic retinopathyThiocolchicine
The invention provides methods of inhibiting angiogenesis in an individual by administering a composition (such as protein containing composition) comprising colchicine or thiocolchicine dimer. The composition is in an amount that is effective in inhibiting angiogenesis but is in some embodiments insufficient to induce significant cytotoxicity in the individual. The methods described herein are useful for treating angiogenesis-associated diseases, such as age-related macular degeneration, diabetic retinopathy, rheumatic arthritis, psoriasis, and cancer.
Owner:ABRAXIS BIOSCI LLC
Methods for treating acromegaly and giantism with growth hormone antagonists
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.
Owner:OHIO UNIV EDISON ANIMAL BIOTECH INST
Conjugates of rgd peptides and porphyrin or (bacterio) chlorohyll photosynthesizers and their uses
Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and normeoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.
Owner:YEDA RES & DEV CO LTD
Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
ActiveUS20120294801A1Ultrasonic/sonic/infrasonic diagnosticsOrganic active ingredientsPorphyrinWilms' tumor
Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.
Owner:YEDA RES & DEV CO LTD
Alkoxy compounds for disease treatment
ActiveUS7982071B2Reducing ischemiaPrevent degradationBiocideSenses disorderAlkoxy groupDisease treatment
Owner:ACUACELA INC
Therapeutic Agent For Ophthalmic Diseases
A therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. Laennec, the active ingredient, exhibits a therapeutic effect on a wide variety of ophthalmic diseases by increasing tears and the like and is highly safe even though it is an animal-derived component. Therefore, the therapeutic agent is applicable to the prevention and / or treatment of various types of ophthalmic diseases, particularly corneal disorders, dry eye, asthenopia, inflammatorily ophthalmic diseases (e.g., meibomian gland dysfunction, Stevens-Johnson syndrome, Sjogren syndrome, uveitis) and ophthalmic diseases caused by active oxygen (e.g., cataract, glaucoma, age-related macular degeneration, optic disc atrophy).
Owner:HIBINO SAWAKO
Targeting complement factor H for treatment of diseases
ActiveUS20080221011A1Improve survivalSenses disorderPeptide/protein ingredientsFactor iiComplement factor I
The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion.
Owner:MUSC FOUND FOR RES DEV +1
Prevention and treatment of complement-associated eye conditions
The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
Owner:GENENTECH INC
Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function
Owner:UNIV OF SOUTHERN CALIFORNIA
Use of ocular vitamins in conjunction with other treatment methods for AMD
The present invention is directed to methods for enhancing current treatment regimens for age-related macular degeneration (AMD). The methods of the invention include intraocular delivery of AMD compositions along with antioxidant compositions. Alternatively, the methods of the invention include a daily regimen of ocular vitamin consumption in conjunction with other treatment methods for AMD.
Owner:ALCON INC
Compounds for treating ophthalmic diseases and disorders
Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.
Owner:ACUACELA INC
5'-and 3'-capped aptamers and uses therefor
InactiveUS20050096290A1Reduce sensitivityImprove stabilitySenses disorderAntipyreticNeovascularizationAnti vegf
The invention provides compositions and methods for the treating disease using aptamers having 5′-5′ and 3′-3′ inverted nucleotide capped ends. In particular, the invention provides 5′-5′ and 3′-3′ capped anti-VEGF aptamers for the treatment of neovascularization-related diseases and disorders including age-related macular degeneration.
Owner:(OSI) EYETECH INC
Method to treat age-related macular degeneration
InactiveUS6942655B2Prevent and alleviate and delay onsetInhibit progressLaser surgeryDiagnosticsDisease areaCombined treatment
Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue and results in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and scatter threshold laser coagulation therapy surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Threshold laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.
Owner:MINU
Method for treating visual impairment through the prophylactic administration of a Morinda citrifolia-based naturaceutical
InactiveUS20030134002A1Promote resultsInhibit and prevent and reverse macular degenerationBiocideUnknown materialsDiabetic retinopathyRetinitis pigmentosa
Implementation of the present invention takes place in association with the utilization of one or more processed products produced from the Indian Mulberry plant, scientifically known as Morinda citrifolia L., to treat one or more eye disorders that affect vision, such as glaucoma, diabetic retinopathy, retinitis pigmentosa, cataracts, age-related macular degeneration, night blindness, color blindness, and other related conditions. The processed Morinda citrifolia products from the Indian Mulberry plant may be in the form of a dietary supplement, eye drops, or in another suitable form.
Owner:TAHITIAN NONI INT INC
Ophthalmic treatment apparatus
InactiveUS20050177019A1Easy to useIncrease exposureMedical devicesMedical applicatorsGreek letter betaOcular operation
Owner:RETINALABS COM
Tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK SHARP & DOHME CORP
Tyrosine kinase inhibitors
InactiveUS20060025426A1Organic active ingredientsBiocideDiabetic retinopathyTyrosine-kinase inhibitor
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.
Owner:MERCK SHARP & DOHME CORP
Novel compounds for treatment of cancer and disorders associated with angiogenesis function
Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating cell growth, cell cycle, apoptosis, or gene expression.
Owner:UNIV OF SOUTHERN CALIFORNIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com